Approval · Notice of Compliance 8766 · 2007
REACTINE: Notice of Compliance 8766
Issued May 4, 2007
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 8766
- Date
- May 4, 2007
- Company
- Mcneil Consumer Healthcare
- Product type
- Nonprescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Addition of indications: nasal congestion, along with itchy nose and throat; all as part of the symptom constellation
- Therapeutic class
- Histamine h1 receptor antagonist
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| REACTINE | Not yet assigned | — |
Medicinal ingredients
- CETIRIZINE HYDROCHLORIDE 5 MG per TAB
- CETIRIZINE HYDROCHLORIDE 10 MG per TAB
- CETIRIZINE HYDROCHLORIDE 20 MG per TAB